Abstract

Immunotherapy has recently shown important clinical successes in a substantial number of oncology indications. Additionally, the tumor somatic mutation load has been shown to associate with response to these therapeutic agents, and specific mutational signatures are hypothesized to improve this association, including signatures related to pathogen insults. We sought to study in silico the validity of these observations and how they relate to each other. We first addressed the question whether somatic mutations typically involved in cancer may increase, in a statistically meaningful manner, the similarity between common pathogens and the human exome. Our study shows that common mutagenic processes like those resulting from exposure to ultraviolet light (in melanoma) or smoking (in lung cancer) increase, in the upper range of biologically plausible frequencies, the similarity between cancer exomes and pathogen DNA at a scale of 12 to 16 nucleotide sequences (corresponding to peptides of 4 – 5 amino acids). Second, we investigated whether this increased similarity is due to the specific mutation distribution of the considered mutagenic processes or whether uniformly random mutations at equal rate would trigger the same effect. Our results show that, depending on the combination of pathogen and mutagenic process, these effects need not be distinguishable. Third, we studied the impact of mutation rate and showed that increasing mutation rate generally results in an increased similarity between the cancer exome and pathogen DNA, again at a scale of 4 – 5 amino acids. Finally, we investigated whether the considered mutational processes result in amino-acid changes with functional relevance that are more likely to be immunogenic. We showed that functional tolerance to mutagenic processes across species generally suggests more resilience to mutagenic processes that are due to exposure to elements of nature than to mutagenic processes that are due to exposure to cancer-causing artificial substances. These results support the idea that recognition of pathogen sequences as well as differential functional tolerance to mutagenic processes may play an important role in the immune recognition process involved in tumor infiltration by lymphocytes.

Highlights

  • IntroductionThe copyright holder for this preprint It is made available under treatment of cancer

  • In the upper range of biologically plausible mutation rates, mutational processes enriched in specific alterations resulting from exposure to these common mutagens lead to exome changes that increase the similarity of mutated peptides to peptides of similar sizes originating from common pathogens

  • Our in-silico results show that, in general, the typical stochastic mutational processes encountered in the major cancer indications with abundant neoantigens do appear to shift the peptide distribution of the modified exome in a mutagen-specific manner but universally towards a landscape that appears more similar to pathogenic insult

Read more

Summary

Introduction

The copyright holder for this preprint It is made available under treatment of cancer. The rates of response vary by indication, outlining the important role of identifying the patients most likely to respond [2,3,4,5]. The analysis of the data in large scale genomic efforts including The Cancer Genome Atlas (TCGA [6]) has identified universal characteristics of the tumor and its environment that ellicit potential recognition by the host immune system. It is important to understand the causality and mechanism of action that drives the heterogenous composition of the tumor and its environment and the heterogeneity of response to immunotherapy, in order to select the right patients for treatment, potential combinations, and potential for early intervention

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call